TAOK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL589391	0.75	2/20
SCHEMBL1960479	0.74	2/20
SCHEMBL589388	0.66	2/20
SCHEMBL2251439	0.65	2/20
SCHEMBL1709769	0.64	2/20
Hydrochloric Acid (SCHEMBL5226467)	0.60	2/20
SCHEMBL2252302	0.60	2/20
SCHEMBL2255402	0.60	2/20
SCHEMBL823917	0.59	2/20
Hydrochloric Acid (SCHEMBL5228442)	0.59	2/20
SCHEMBL2249540	0.58	2/20
SCHEMBL3559746	0.57	2/20
SCHEMBL3558128	0.57	2/20
SCHEMBL4978426	0.57	2/20
SCHEMBL5225821	0.57	2/20
SCHEMBL5225849	0.57	2/20
Hydrochloric Acid (SCHEMBL4984127)	0.56	2/20
SCHEMBL5225853	0.56	2/20
SCHEMBL10042735	0.51	2/20
SCHEMBL3709330	0.42	2/20

Clinical trials — most relevant to TAOK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK	PHASE3	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma	PHASE2	RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm	nan	COMPLETED
TAKO-TSUBO Cardiomyopathy and Genetic	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Genetic Studies Spermatogenic Failure	nan	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	nan	UNKNOWN
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Natural History and Risk Factors of TAO	nan	UNKNOWN
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy.	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TAOK2 binder may also engage these)

Protein	Name	Similarity
Q6ZQ29	—	0.996	Q6ZQ29 →
Q9JLS3	—	0.996	Q9JLS3 →
Q80XI6	—	0.986	Q80XI6 →
Q8K330	—	0.986	Q8K330 →
Q66HA1	—	0.984	Q66HA1 →
O70405	—	0.984	O70405 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.984	landscape →
D3ZG83	—	0.983	D3ZG83 →
Q76LL6	—	0.983	Q76LL6 →
Q8VDG6	—	0.983	Q8VDG6 →
Q3TES0	—	0.983	Q3TES0 →
O54967	—	0.982	O54967 →
Q8VDP4	—	0.982	Q8VDP4 →
MAP3K10	Mitogen-activated protein kinase kinase kinase 10	0.982	landscape →
Q60700	—	0.982	Q60700 →
Q76N89	—	0.981	Q76N89 →
Q3UJB9	—	0.981	Q3UJB9 →
Q9Z136	—	0.981	Q9Z136 →
Q9Y4B5	—	0.981	Q9Y4B5 →
Q5RJI5	—	0.981	Q5RJI5 →
A1L3T7	—	0.981	A1L3T7 →
Q8BL43	—	0.980	Q8BL43 →
Q76M68	—	0.980	Q76M68 →
Q8BXP5	—	0.980	Q8BXP5 →
Q9BQI7	—	0.980	Q9BQI7 →
Q66L42	—	0.980	Q66L42 →
A2A9T0	—	0.980	A2A9T0 →
Q9JIR0	—	0.980	Q9JIR0 →
B2DD29	—	0.980	B2DD29 →
Q9UFB7	—	0.980	Q9UFB7 →